Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Raymond

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
Investigational New Drugs|May 17, 2011
Antiangiogenic treatments and mechanisms of action in renal cell carcinomaSylvie Négrier, Eric Raymond
Expert Opinion on Investigational Drugs|October 17, 2008
Mechanism of action of rapalogues: the antiangiogenic hypothesisSandrine Faivre, Eric Raymond
Accounts of Chemical Research|June 18, 2003
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trialsLaurent Meijer, Eric Raymond
Therapeutic Advances in Gastroenterology|September 5, 2013
Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinibAaron I Vinik, Eric Raymond
Current Opinion in Oncology|March 19, 2015
Reinvention of chemotherapy: drug conjugates and nanoparticlesTu Nguyen-Ngoc, Eric Raymond
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 28, 2011
Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumorsEmma D Deeks, Eric Raymond
Expert Review of Anticancer Therapy|December 25, 2008
Early development of sunitinib in hepatocellular carcinomaAndrew X Zhu, Eric Raymond
Seminars in Oncology|August 8, 2006
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitorsSandrine Faivre, Siham Djelloul, Eric Raymond
Nature Reviews. Drug Discovery|August 3, 2006
Current development of mTOR inhibitors as anticancer agentsSandrine Faivre, Guido Kroemer, Eric Raymond
Cancer Metastasis Reviews|February 18, 2011
Future perspectives on neuroendocrine tumorsDaniel Castellano, Ramón Salazar, Eric Raymond
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
Investigational New Drugs|May 17, 2011
Antiangiogenic treatments and mechanisms of action in renal cell carcinomaSylvie Négrier, Eric Raymond
Expert Opinion on Investigational Drugs|October 17, 2008
Mechanism of action of rapalogues: the antiangiogenic hypothesisSandrine Faivre, Eric Raymond
Accounts of Chemical Research|June 18, 2003
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trialsLaurent Meijer, Eric Raymond
Therapeutic Advances in Gastroenterology|September 5, 2013
Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinibAaron I Vinik, Eric Raymond
Current Opinion in Oncology|March 19, 2015
Reinvention of chemotherapy: drug conjugates and nanoparticlesTu Nguyen-Ngoc, Eric Raymond
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 28, 2011
Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumorsEmma D Deeks, Eric Raymond
Expert Review of Anticancer Therapy|December 25, 2008
Early development of sunitinib in hepatocellular carcinomaAndrew X Zhu, Eric Raymond
Seminars in Oncology|August 8, 2006
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitorsSandrine Faivre, Siham Djelloul, Eric Raymond
Nature Reviews. Drug Discovery|August 3, 2006
Current development of mTOR inhibitors as anticancer agentsSandrine Faivre, Guido Kroemer, Eric Raymond
Cancer Metastasis Reviews|February 18, 2011
Future perspectives on neuroendocrine tumorsDaniel Castellano, Ramón Salazar, Eric Raymond
Pageof 18